Compare BPRN & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPRN | NBP |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5M | 275.2M |
| IPO Year | 2022 | N/A |
| Metric | BPRN | NBP |
|---|---|---|
| Price | $34.84 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 4.8K | ★ 1.2M |
| Earning Date | 04-23-2026 | 04-07-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 74.84 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.96 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $38.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.21 | $1.67 |
| 52 Week High | $37.99 | $5.19 |
| Indicator | BPRN | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 25.14 |
| Support Level | $34.66 | N/A |
| Resistance Level | $36.53 | $2.73 |
| Average True Range (ATR) | 0.70 | 0.12 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 61.93 | 10.67 |
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.